THERAPY DOSSIER · th-5e17288bebba

p-OH SB-3CT, the hydroxylated active metabolite of the thiirane gelatinase inhibitor SB-3CT

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: p-OH SB-3CT; SB-3CT
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26588471 ↗2015No effect reported

Early Gelatinase Activity Is Not a Determinant of Long-Term Recovery after Traumatic Brain Injury in the Immature Mouse.

MouseTBIControlled cortical impactC57Bl/6JMalen = 112 mice in total; n = 15 per group for long-term behaviour…Subcutaneous25 mg/kg per injection, formulated at 5.0 mg/mL in 65% prop…First dose 2 h post-injury, treatment confined to the first 48 h

Model: Controlled cortical impact traumatic brain injury after craniotomy, 4.5 m/s, 1.73 mm depth, 150 ms sustained depression, 3.0 mm convex tip; sham mice had craniotomy only

Active and pro forms of MMP-2 and MMP-9 were elevated at 48 h and p-OH SB-3CT crossed the blood-brain barrier at therapeutic concentrations and attenuated in situ gelatinase activity, yet it did not alter hyperactivity, water maze deficits, reduced sociability, tissue loss, surviving dentate neuron…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.

Loading the evidence…